Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report.

ABSTRACT:

Background

Uveal melanoma (UM), the most common primary intraocular malignancy in adults, has limited systemic treatment options in the metastatic setting. Recent insights into cysteinyl leukotriene receptors (CysLTRs)-particularly CYSLTR2 mutations (prevalence 2%-4%)-suggest new therapeutic approaches for patients who progress despite standard therapies.

Case

We report the case of a 59-year-old male with metastatic UM harboring a CYSLTR2 mutation. The patient experienced progression after multiple systemic treatments, including immune checkpoint inhibitors (ipilimumab/nivolumab, pembrolizumab), chemotherapy (dacarbazine, gemcitabine/treosulfan), and local radiotherapy. Lacking human leukocyte antigen-A∗02:01, he was ineligible for tebentafusp. In November 2022, next-generat

SUBMITTER: Smarsly D 

PROVIDER: S-EPMC12741292 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature